Patents by Inventor Hung Do

Hung Do has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210260567
    Abstract: Phosphine phosphonate and phenoxyphosphine ligands bearing polyethylene glycol (PEG) chains are used as described herein to produce heterobimetallic catalysts. The ligands can be metallated selectively with palladium or nickel and secondary metal ions to provide well-defined heterobimetallic compounds. These heterobimetallic complexes exhibit accelerated reaction rates and greater thermal stability in olefin polymerization compared to other catalysts.
    Type: Application
    Filed: June 26, 2019
    Publication date: August 26, 2021
    Applicant: University of Houston System
    Inventors: Loi Hung Do, Zhongzheng Cai, Thi Tran, Dawei Xiao
  • Patent number: 11097015
    Abstract: Provided herein are polypeptides comprising one or more non-native cysteine residues that form a disulfide bridge between non-native cysteines within the protein or between non-native cysteines of two monomers of the protein. Such modified human polypeptides are useful in treatment of genetic diseases via enzyme replacement therapy and/or gene therapy.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: August 24, 2021
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hung Do, Ce Feng Liu
  • Publication number: 20210162075
    Abstract: Provided herein are improved gene therapy vectors and methods of use, in some embodiments, comprising sequences for improved expression and cellular targeting of a therapeutic protein.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 3, 2021
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Hung Do, Steven Tuske, Russell Gotschall, Ce Feng Liu
  • Patent number: 10874750
    Abstract: Provided herein are improved gene therapy vectors and methods of use, in some embodiments, comprising sequences for improved expression and cellular targeting of a therapeutic protein.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hung Do, Steven Tuske, Russell Gotschall, Ce Feng Liu
  • Patent number: 10814008
    Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 27, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Hung Do
  • Publication number: 20200171133
    Abstract: Provided are pharmaceutical formulations comprising a recombinant acid ?-glucosidase, wherein the recombinant acid ?-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.
    Type: Application
    Filed: October 16, 2019
    Publication date: June 4, 2020
    Inventors: Hing Char, Sergey Tesler, Wendy Sunderland, Enrique Diloné, Russell Gotschall, Hung Do
  • Patent number: 10660972
    Abstract: Described herein are methods of making targeting peptides conjugated to a recombinant lysosomal enzyme by modifying the amino (N)-terminus and one or more lysine residues on a recombinant human lysosomal enzyme using a first crosslinking agent to give rise to a first crosslinking agent modified recombinant human lysosomal enzyme, modifying a lysine or cysteine within a short extension linker at the carboxyl (C)-terminus on a variant IGF-2 peptide having a short extension linker using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short extension linker. Also described herein are conjugates synthesized using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: May 26, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Hung Do
  • Publication number: 20200147241
    Abstract: Provided herein are polypeptides comprising one or more non-native cysteine residues that form a disulfide bridge between non-native cysteines within the protein or between non-native cysteines of two monomers of the protein. Such modified human polypeptides are useful in treatment of genetic diseases via enzyme replacement therapy and/or gene therapy.
    Type: Application
    Filed: October 10, 2019
    Publication date: May 14, 2020
    Inventors: Hung DO, Ce Feng LIU
  • Patent number: 10512676
    Abstract: Provided are pharmaceutical formulations comprising a recombinant acid ?-glucosidase, wherein the recombinant acid ?-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: December 24, 2019
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hing Char, Sergey Tesler, Wendy Sunderland, Enrique Diloné, Russell Gotschall, Hung Do
  • Publication number: 20190343968
    Abstract: Provided herein are improved gene therapy vectors and methods of use, in some embodiments, comprising sequences for improved expression and cellular targeting of a therapeutic protein.
    Type: Application
    Filed: April 30, 2019
    Publication date: November 14, 2019
    Inventors: Hung DO, Steven TUSKE, Russell GOTSCHALL, Ce Feng LIU
  • Publication number: 20180185503
    Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.
    Type: Application
    Filed: February 8, 2018
    Publication date: July 5, 2018
    Applicant: Amicus Therapeutics, Inc.
    Inventor: Hung DO
  • Patent number: 9889203
    Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 13, 2018
    Assignee: AMICUS THERAPEUTICS, INC.
    Inventor: Hung Do
  • Publication number: 20170319710
    Abstract: Described herein are methods of making targeting peptides conjugated to a recombinant lysosomal enzyme by modifying the amino (N)-terminus and one or more lysine residues on a recombinant human lysosomal enzyme using a first crosslinking agent to give rise to a first crosslinking agent modified recombinant human lysosomal enzyme, modifying a lysine or cysteine within a short extension linker at the carboxyl (C)-terminus on a variant IGF-2 peptide having a short extension linker using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short extension linker. Also described herein are conjugates synthesized using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.
    Type: Application
    Filed: November 9, 2016
    Publication date: November 9, 2017
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventor: HUNG DO
  • Patent number: 9545450
    Abstract: Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (N)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (N)-terminus on a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the IGF2/CI-MPR receptor and cellular uptake using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: January 17, 2017
    Assignee: Amicus Therapeutics Inc.
    Inventor: Hung Do
  • Patent number: 9374545
    Abstract: A column readout amplifier and imaging array using the same method are disclosed. The column readout amplifier includes a signal amplifier having an amplifier signal output, a first filter capacitor, a buffer amplifier having a buffer amplifier input and a buffer amplifier output, and a switching network. The switching network connects the amplifier signal output to the buffer amplifier input and the buffer amplifier output to the first filter capacitor during a first time period, and connects the amplifier signal output directly to the first filter capacitor during a second time period. The time periods can be of fixed duration or determined by the difference in potential between the input and output of the buffer amplifier. The column readout amplifier can be used in an imaging array to readout columns of pixels.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: June 21, 2016
    Assignee: BAE Systems Imaging Solutions Inc.
    Inventors: Boyd Fowler, Hung Do, Xinqiao Liu
  • Publication number: 20160129126
    Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 12, 2016
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventor: Hung DO
  • Patent number: 9279007
    Abstract: Polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) are disclosed. Also disclosed are fusion proteins comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide. Also disclosed are protein expression vectors comprising a promoter operably linked to a first DNA sequence encoding a signal sequence comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) and a second DNA sequence encoding a heterologous polypeptide fused in frame to the first DNA sequence. Further disclosed are methods of producing a polypeptide comprising expressing a fusion protein comprising a polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide and recovering the heterologous polypeptide.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: March 8, 2016
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Hung Do
  • Patent number: 9061731
    Abstract: A self-charging electric bicycle that includes a solar panel disposed upon a back plate above the rear wheel, a first dynamo operationally engaged by the rotational force of the front wheel, a second dynamo operationally engaged by the rotational force of the rear wheel, and a third dynamo operationally engaged at a high gear ratio by a second chain in operational communication with the bicycle pedal crank, wherein an electric battery disposed within a housing upon the bicycle frame is charged and recharged when the bicycle is moved and pedaled and when sunlight is incident the solar panel, whereby an electric motor is activatable to drive the bicycle, as desired.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: June 23, 2015
    Inventor: Hung Do
  • Publication number: 20150076321
    Abstract: A column readout amplifier and imaging an-ay using the same method are disclosed. The column readout amplifier includes a signal amplifier having an amplifier signal output, a first filter capacitor, a buffer amplifier having a buffer amplifier input and a buffer amplifier output, and a switching network. The switching network connects the amplifier signal output to the buffer amplifier input and the buffer amplifier output to the first filter capacitor during a first time period, and connects the amplifier signal output directly to the first filter capacitor during a second time period. The time periods can be of fixed duration or determined by the difference in potential between the input and output of the buffer amplifier. The column readout amplifier can be used in an imaging array to readout columns of pixels.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 19, 2015
    Inventors: Boyd Fowler, Hung Do, Xinqiao Liu
  • Patent number: 8962564
    Abstract: Described herein are variant, recombinant ?-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type ?-glucocerebrosidase. Also provided herein are variant, recombinant ?-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type ?-glucocerebrosidase. Further described herein are variant, recombinant ?-glucocerebrosidase proteins that can have amino acid variations at one or more of the following positions: 316, 317, 321 and 145. Methods of making the variant, recombinant ?-glucocerebrosidase proteins are also described as well as methods of treating patients having lysosomal storage diseases.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: February 24, 2015
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Hung Do